At its meetings on 4 and 30 June 2025, the AIFA Board of Directors approved the eligibility for NHS reimbursement of one new chemical entity and two extensions of therapeutic indications for a medicinal product already reimbursed for other indications.

The newly approved chemical entity is Kapruvia (difelikefalin), indicated for the treatment of pruritus in adults with chronic kidney disease undergoing dialysis. Kapruvia works by stimulating human kappa opioid receptors, which play a role in modulating the perception of itching.

The two extensions of therapeutic indications concern the antiviral Prevymis (letermovir), which helps prevent the development or reactivation of cytomegalovirus (CMV) disease in immunocompromised patients following a stem cell or kidney transplant.